ISAL 2019 | Bob Löwenberg’s perspective on CAR-T and immunotherapy for AML

Bob Löwenberg

Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, discusses his thoughts on CAR T-cell therapy and other immuno-oncology treatments for acute myeloid leukemia (AML). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video  
Similar topics